DOMA Perpetual Proposes New Directors Amidst Pacira's Troubling Performance and Stock Downtrend

DOMA Perpetual's Bold Move to Nominate New Directors for Pacira BioSciences

In a significant development in the world of healthcare investment, DOMA Perpetual Capital Management has announced the nomination of three candidates to Pacira BioSciences' Board of Directors. This comes as Pacira's stock has dropped a staggering 56% over the last decade and 68% over the past five years. Currently, under the leadership of CEO and Board member Frank Lee, the stock has decreased by 30%, indicating a troubling trend that has concerned shareholders.

DOMA, which owns approximately 7.1% of Pacira's outstanding shares, believes that the company has been poorly managed, evidenced by consistently missed earnings and a lack of profitability over the last two years. The firm argues that the existing Board has failed to provide adequate financial controls and oversight, which has hampered the company's performance.

The Candidates

The three nominees put forth by DOMA are:
1. Christopher Dennis, MD, MBA, FAPA – A seasoned physician executive with over 25 years of experience predominantly focused on behavioral health and substance use disorders. His strong background in healthcare can offer invaluable insights into Pacira's operations.
2. Oliver Benton Curtis III – A former federal prosecutor with expertise in regulatory enforcement and internal investigations. His legal background will be crucial to address the compliance and governance challenges faced by the Board.
3. Eric de Armas – DOMA's CFO and CCO, who brings over 20 years of experience in finance, risk management, and corporate governance, ensuring that the financial interests of shareholders will be prioritized.

The appointment of these directors is poised to instigate a major shift in how Pacira approaches its business strategy and management practices. DOMA emphasizes that these candidates have the requisite expertise to ensure shareholders' interests are effectively represented.

Investment and Financial Performance

DOMA has raised concerns about Pacira's rising management compensation, which has reached unsustainable levels, currently accounting for nearly 7% of the company's total market capitalization. As Pacira failed to generate value for its shareholders, the exorbitant pay levels for executives like Frank Lee have been seen as unjustifiable by investors. DOMA's successful lobbying for a change in the Board's composition aims to secure better management accountability and strategic oversight.

Moreover, the report outlines a critical view of the company's strategic direction. Instead of expanding its portfolio through new pipeline drug acquisitions, DOMA argues that Pacira should prioritize the sale of the company to a larger firm that can effectively market its leading drug, EXPAREL. Known for being the sole non-opioid pain medication approved for use in surgical procedures in the U.S., EXPAREL has the potential to significantly improve patient care amid the ongoing opioid crisis.

The Call to Action

DOMA insists that immediate action must be taken to replace Frank Lee with an interim CEO and expedite the sale of Pacira. This call underscores the growing frustration among shareholders who have witnessed declines in stock prices while management's compensation continues to rise unchecked.

In summary, DOMA Perpetual's nomination of highly qualified candidates aims not simply to change the faces in the boardroom but to initiate a vital transformation in Pacira's governance and operational strategy. With new leadership, there’s hope that the company will embrace a path toward recovery, ensuring that the interests of shareholders are prioritized and ultimately leading to a resurgence in stock price and corporate value. The upcoming annual meeting will be a critical juncture as shareholders consider these nominees and their outlined vision for Pacira's future.